Daewoong Co., Ltd. (003090.KS) Stock

003090.KS logo

Daewoong Co., Ltd.

003090.KSSouth Korea
Healthcare

Company profile

Daewoong reported revenue of 2.07 trillion KRW for fiscal year 2025, up 6.8% from fiscal year 2024, and net income of 175.06 billion KRW. That is a net profit margin of 8.5% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 492.71 billion KRW, up 2.3% from a year before. Its largest business segment, Pharmaceutical Manufacturing and Sales, brought in 94% of segment revenue in fiscal year 2024. In Q1 2026 it reported net income of 35.26 billion KRW, against net income of 26.16 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.81 trillion KRW in fiscal year 2023 to 2.07 trillion KRW in fiscal year 2025, 6.8% a year on average. Daewoong reports about 404 full-time employees.

What stands out

  • Net income more than tripled in fiscal year 2025, from 57.89 billion KRW in fiscal year 2024.
  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Daewoong Co., Ltd.

Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1945 and is headquartered in Seongnam-si, South Korea.

Largest shareholders

  • Jae-Seung Yoon11.91 %11.91%
  • Daewoong Endowment Foundation9.98%
  • Jae-yong Yoon7.011 %7.01%
  • Young Yoon5.423 %5.42%
  • National Pension Service of Korea3.98%

Share of the company, as of September 25, 2026

Leadership

  • Yeong-Hwan Yoon — Chairman and Chief Executive Officer, 91
  • Nan-Young Jeong — Chief Executive Officer, President and Representative Director, 83

How much revenue does Daewoong make?

Daewoong reported 2.07 trillion KRW in revenue for fiscal year 2025, up 6.8% from 1.94 trillion KRW in fiscal year 2024. In Q1 2026 revenue was 492.71 billion KRW.

What is Daewoong's largest business segment?

Pharmaceutical Manufacturing and Sales, with 2.07 trillion KRW or 94% of segment revenue in fiscal year 2024. Next: Service Provision (5%) and Real Estate Rental (1%).

What companies are similar to Daewoong?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include HK inno.N Corporation (195940.KQ), Chong Kun Dang Pharmaceutical Corp. (185750.KS), Boryung Corporation (003850.KS), JW Pharmaceutical Corporation (001060.KS).

Has Daewoong made a profit in recent years?

Net income by fiscal year: FY2021, 78.73 billion KRW; FY2022, 102.57 billion KRW; FY2023, 152.67 billion KRW; FY2024, 57.89 billion KRW; FY2025, 175.06 billion KRW. It was profitable in each of these years.

How has Daewoong's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.51 trillion KRW; FY2022, 1.70 trillion KRW; FY2023, 1.81 trillion KRW; FY2024, 1.94 trillion KRW; FY2025, 2.07 trillion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees404
HeadquartersSeongnam-si, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
244 Galmachi-ro, Seongnam-si
Phone
82 2 550 8800
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Daewoong Co., Ltd. (003090.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003090.KS

LinkedInLinkedInXXYouTubeYouTube